Q-omics provides the consensus-scored OR4C12 profile across patient tissues and cancer cell-line models. OR4C12 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, OR4C12 is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, OR4C12 RNA expression shows 6,002 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, HNSC, and STAD as cancer lineages where OR4C12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR4C12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR4C12 survival associations across molecular data types. OR4C12 RNA expression shows survival associations in the most cancer types (8), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR4C12 RNA expression–survival associations across cancer types. High OR4C12 expression shows unfavorable associations in CHOL, TGCT, GBM, LUSC and SCLC, but favorable associations in ESCA. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify CHOL as the clearest survival context for OR4C12 RNA expression.
This table summarizes OR4C12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR4C12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR4C12 shows higher tumor expression in HNSC and PRAD. The HNSC box plot shows higher OR4C12 RNA expression in tumor versus normal tissue (log2 FC = +0.006, t-test p = .043).
This table shows molecular features associated with OR4C12 in patient tissues and cancer cell lines. In patient samples, OR4C12 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR4C12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
